Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Stock Forecast & Price Target
Amneal Pharmaceuticals, Inc. Class A Common Stock · NASDAQ
$18.77+0.68 (+3.76%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Amneal Pharmaceuticals, Inc. Class A Common Stock, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $13.00 to $23.00, a moderate spread. The average target of $16.60 sits 12% below the current $18.77. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 3% this year and 7% next, consensus EPS building from about $0.25 next quarter toward $1.12 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Amneal Pharmaceuticals, Inc. Class A Common Stock.
As of Jul, 5 of 5 firms rate AMRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AMRX EPS & revenue forecast
EPS · NEXT QUARTER
$0.25
Range $0.22 – $0.28 · 5 analysts · +45% YoY
Next period, 5 analysts expect Amneal Pharmaceuticals, Inc. Class A Common Stock to earn $0.25 a share (range $0.22 – $0.28), versus $0.17 a year earlier. Full-year consensus is $0.98, growing to $1.12 the year after.
REVENUE · NEXT QUARTER
$816.4M
Range $804.8M – $822.6M · 5 analysts · +3% YoY
Revenue is expected to reach $816.4M (range $804.8M – $822.6M), +3.0% year-over-year. Full-year consensus is $3.1B, rising to $3.3B next year.
Top analysts covering Amneal Pharmaceuticals, Inc. Class A Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AMRX.
#1
David Amsellem
Piper Sandler · Rank #95
Buy
$13.00-30.7% to target
Overall win rate
50%
+ Follow
#2
Balaji Prasad
Barclays · Rank #147
Buy
$11.00-41.4% to target
Overall win rate
44%
+ Follow
#3
LS
Les Sulewski
Truist Securities
Buy
No targeton AMRX
Coverage
—
+ Follow
#4
CS
Chris Schott
JP Morgan
Buy
$18.00-4.1% to target
Coverage
—
+ Follow
#5
Ashwani Verma
UBS
Buy
$23.00+22.5% to target
Coverage
—
+ Follow
AMRX stock forecast FAQ
What is AMRX's average 12-month price target?+
The 5 analysts with a live target average $16.60 for Amneal Pharmaceuticals, Inc. Class A Common Stock over the next 12 months, ranging from a $23.00 high to a $13.00 low.
Is AMRX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AMRX?+
The Street-high target is $23.00 (UBS), and the Street-low is $13.00 (Piper Sandler). The average of all 5 active targets is $16.60.
How many Wall Street analysts cover AMRX?+
5 analysts have an active rating on Amneal Pharmaceuticals, Inc. Class A Common Stock, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering AMRX?+
Among analysts who currently cover AMRX, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #95). Their current call is Buy with a $13.00 target.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's projected EPS for next quarter?+
The consensus estimate is $0.25 per share (range $0.22 – $0.28) across 5 analysts. Full-year EPS is projected at $0.98, rising to $1.12 the following year.
How much revenue is Amneal Pharmaceuticals, Inc. Class A Common Stock expected to report next quarter?+
Consensus revenue is $816.4M (range $804.8M – $822.6M). Full-year revenue is projected at $3.1B, growing to $3.3B next year.
Have analysts been upgrading or downgrading AMRX lately?+
As of Jul, 5 of 5 firms rate AMRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AMRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
